New drug approvals were off to a slow start in 2010 but addressed indications outside the usual areas. In April, the first autologous cell therapy, Provenge (sipuleucel-T), was approved, and last month, Amgen's RANK ligand antagonist (denosumab) was also registered for marketing. Fingolimod, the first synthetic sphingosine-1-phosphate agonist in multiple sclerosis, was given a favorable recommendation, and positive trial data came in for the antisense drug, mipomersen, as well as ipilimumab, epratuzumab and pertuzumab, which addresses a new epitope on HER2.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peng, W. Drug pipeline: Q210. Nat Biotechnol 28, 640 (2010). https://doi.org/10.1038/nbt0710-640
Issue Date:
DOI: https://doi.org/10.1038/nbt0710-640
This article is cited by
-
Amgen's bone-metastasis win
Nature Biotechnology (2011)